Global Holdings, Inc. (GBHD) Acquires the Exclusive Rights to a Pharmaceutical Treatment of Endometriosis

Virginia Beach, VA / ACCESSWIRE / October 28, 2014 / Global Holdings, Inc. (GBHD.OTC) announces that it acquired the exclusive licensed rights for a pharmaceutical product for the treatment of endometriosis.

Endometriosis, one of the most common gynecological disorders that is estimated to affect approximately one in ten women in their reproductive (child-bearing) years and is the number one cause of infertility.

This novel pharmaceutical compound completely suppresses endometriosis in women before and after the on-set of the disease. This product has a patent-pending application with the US Patent and Trademark Office.

More information about the pharmacology of this endometriosis treatment and other relevant information will be forthcoming in ensuing announcements.

For further information about this release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, www.gbhd.net.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain forward information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competitions.

CONTACT:

Global Holdings, Inc.
Rich Kaiser, Yes International, 757-306-6090

 

SOURCE: Global Holdings, Inc.